lun Law Offices 北京市东城区 金宝街 89 号令宝大厦 11 层 11F Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing, Ch 电话(Tel):(86 10)6652 3388 传真(Fax):(86 10)6652 3399 网址(Website): www.junzejun.com 北京市君泽君律师事务所 关于北京双鹭药业股份有限公司 2024 年年度股东大会的法律意见 致:北京双鹭药业股份有限公司 北京双鹭药业股份有限公司（以下简称"公司"）2024年年度股东大会（以 下简称"本次股东大会")于 2025年5月22日召开,北京市君泽君律师事务所 (以下简称"本所")接受公司的委托,就公司本次股东大会的相关事宜出具法 律意见。 本所及经办律师依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则(试行)》等规定及本法律意见出具日以前已经发 生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进 行了充分的 ...

Financial Performance - The company experienced significant fluctuations in revenue and profit due to various factors, including changes in the fair value of financial assets and a high base from the previous year's demand for flu treatment drugs [2][3]. - The price reductions from centralized procurement have led to substantial decreases in the prices of key products: Temozolomide decreased by 57%, Lenalidomide by nearly 70%, and the price of Oxaliplatin injection dropped by over 80% [4]. Future Outlook - The company anticipates an improvement in performance next year, as most products involved in national procurement are newly launched and should not face significant price declines [3][4]. - The company has several new products expected to be approved, which may contribute positively to future revenue [3]. R&D and Product Development - The company is focusing on innovative drug development, with several key products in clinical trials, including DT678 and PHP1003, which are expected to address significant medical needs [7]. - The company has increased its R&D investment, with over 60% of its 400+ R&D personnel holding master's degrees or higher [14]. Market Strategy - The company is expanding its overseas market presence, particularly in developing countries, with plans to enter the European and American markets [10]. - Recent products have been included in centralized procurement, which is expected to become a new profit growth point for the company [11]. Investment and Acquisitions - Currently, the company has no plans for refinancing or mergers and acquisitions [8]. - The company holds a 55.69% stake in Beijing New Mile Health Industry Group, which is expected to yield good returns in the future [5][6]. Regulatory and Competitive Landscape - The ongoing centralized procurement policy is likely to continue, but the extent of price reductions may stabilize, leading to a more rational market environment [4]. - The company is committed to increasing R&D investment despite recent performance challenges, aiming to enhance its competitive position in the industry [4].

Core Viewpoint - On its 30th anniversary, Shuanglu Pharmaceutical is facing a historic turning point, reporting a net loss of approximately 74.07 million yuan for 2024, marking its first annual loss since its listing in 2004 [1][4]. Financial Performance - In 2024, Shuanglu Pharmaceutical achieved an operating revenue of approximately 660 million yuan, a year-on-year decline of 35.15%, with a corresponding net profit of -74.07 million yuan, transitioning from profit to loss [4]. - The company had previously seen net profits exceeding 100 million yuan since 2007, peaking at 695 million yuan in 2014, and fluctuating between 200 million and 500 million yuan from 2020 to 2023 [4]. - In the first quarter of 2024, the company reported an operating revenue of approximately 169 million yuan, down 31.1%, and a net profit of approximately 45.97 million yuan, down 34.46% [4]. Product Sales Decline - Multiple key products experienced significant sales declines in 2024, with the oncology and immune regulation products generating sales of 276 million yuan, accounting for 42.69% of total sales, down 27.69% year-on-year [6]. - The sales of the previously promising product, Lenalidomide, accounted for only 4.89% of the oncology product category, with a staggering year-on-year decline of 77.22% [6][7]. - Other product categories, including anti-infection, trauma repair, and cardiovascular products, also saw sales declines of 48.42%, 30.95%, and 33.92% respectively [7]. Financial Asset Impact - The decline in financial assets, particularly the fair value changes in securities investments, significantly impacted the company's performance, with a total loss of approximately 178 million yuan from its holdings in Fosun Pharma, Shouyao Holdings, and Xinghao Pharma [9]. - The fair value changes for these stocks were -22.94 thousand yuan, -161 million yuan, and -16.14 million yuan respectively, contributing to the overall financial downturn [9]. Future Outlook - The company plans to increase R&D investment and has developed a strong product pipeline in oncology, liver disease, antiviral, metabolic regulation, and cardiovascular fields, while also exploring new areas such as diabetes and ophthalmology [5]. - The chairman expressed optimism that the company will recover its performance, viewing 2025 as a year of both challenges and opportunities [5][10].

Group 1: Market Competition and Product Development - The company is adopting a differentiated competition strategy by continuously launching competitive new products and enhancing market promotion and e-commerce platform development [1][2][3] - The newly launched prebiotic and probiotic lozenges are aimed at improving gut microecological balance and supporting immune health, with unique features such as heat and acid resistance [1][3][5] - The company is focusing on developing innovative products to address the challenges posed by the competitive generic drug market, which has thin profit margins [3][5] Group 2: Financial Performance and Challenges - In Q1 2025, the company reported a profit of approximately 45.97 million, with a non-recurring profit of 21 million, impacted by a loss of 110.65 million from two major investments [2][4] - The company's financial performance has been affected by significant price drops in key products due to national procurement policies, with an estimated impact of -170 million in 2024 [4][6] - The company has experienced stock price volatility, with a decline attributed to fluctuations in the market value of its financial assets [4][6][7] Group 3: Future Growth and Strategic Plans - The company plans to enhance its market presence by accelerating the launch of new products and expanding e-commerce sales, aiming for significant sales growth [6][7][8] - The company is actively pursuing the development of GLP-1 long-acting products for type 2 diabetes treatment and weight management, with clinical studies completed and preparations for NDA submission underway [2][11][18] - The company is committed to increasing R&D investment, focusing on innovative drug development to meet the growing health demands of an aging population [6][19][26] Group 4: Stock and Investor Relations - The company has not engaged in stock buybacks recently, which has raised concerns among investors regarding confidence in the company's future [4][25][27] - The total number of shareholders as of March 31, 2025, was reported to be 57,688, indicating a stable investor base [31] - The company is considering suggestions for stock buybacks to enhance investor confidence, although it faces various constraints [25][30][32]

北京双鹭药业股份有限公司 关于第二大股东股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述 或重大遗漏。 北京双鹭药业股份有限公司（以下简称"双鹭药业"、"公司"）于2025 年4 月23 日接到公 司第二大股东新乡白鹭投资集团有限公司（以下简称"新乡白鹭集团"）函告，获悉其所持有公司 的部分股份解除质押，具体事项如下： 一、股东股份解除质押基本情况 1. 本次股份解除质押基本情况 证券代码：002038 证券简称：双鹭药业 公告编号：2025-016 二、股东股份累计质押基本情况 截至公告披露日，新乡白鹭集团及其一致行动人所持质押股份情况如下： | | | | | 合计占 | 合计占 | 已质押 股份情况 | | 未质押 股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 | 持股比例 | 累计被质 | 其所持 | 公司总 | 已质押股 | 占已 | 未质押股 | 占未 | | | | | 押数量 | 股份比 | 股本比 | 份限售和 | ...

北京双鹭药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 22 日披露了 《2024 年年度报告》及《2024 年年度报告摘要》。为建立与投资者良好的沟通机制，使广 大投资者进一步了解公司财务状况、经营情况和未来发展规划，公司定于 2025 年 5 月 14 日（周三）15:00-17:00 在全景网举办 2024 年度业绩说明会，本次年度业绩说明会将采用 网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）在 线参与本次年度业绩说明会。 出席本次网上业绩说明会的人员有：公司董事长兼总经理徐明波先生、独立董事钱令 嘉女士及程隆云女士、董事兼董事会秘书梁淑洁女士、财务负责人冀莉女士。 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 5 月 13 日前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面提交问题。敬请广大投资 者通过全景网系统提交您所关注的问题，便于公司在业绩说明会上对投资者普遍关注的问 题进行回答， ...

北京双鹭药业股份有限公司 一、2024 年年审会计师事务所基本情况 大华会计师事务所（特殊普通合伙）（以下简称"大华所"）成立于 2012 年 2 月，由大 华会计师事务所有限公司转制为特殊普通合伙企业。注册地址为北京市海淀区西四环中路 16 号院 7 号楼 1101，首席合伙人为梁春。截至 2024 年 12 月 31 日合伙人数量：150 人、注 册会计师人数：887 人，其中：签署过证券服务业务审计报告的注册会计师人数：404 人。 大华所在国内重要城市设立了 30 家分支机构。2023 年度业务总收入 32.53 亿元、审计业务 收入 29.49 亿元、证券业务收入 14.89 亿元。 二、聘任年审会计师事务所履行程序 公司于 2024 年 11 月 21 日召开第九届董事会第五次会议、第九届监事会第五次会议审 议通过了《关于续聘大华会计师事务所（特殊普通合伙）为公司 2024 年度审计机构的议 案》，后该议案于 2024 年 12 月 12 日经公司 2024 年第一次临时股东大会审议通过，同意续 聘大华会计师事务所（特殊普通合伙）为公司 2024 年度审计机构，公司独立董事对上述议 案发表了事前认 ...

北京双鹭药业股份有限公司 关于使用自有资金进行短期风险投资事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、风险投资概述 证券代码：002038 证券简称：双鹭药业 公告编号：2025-012 北京双鹭药业股份有限公司（以下简称"公司"）为充分提升公司资金使用效率及资 金收益水平并增强公司盈利能力，2025 年 4 月 21 日公司召开第九届董事会第六次会议审 议通过《关于公司使用自有资金不超过 60,000 万元进行短期风险投资的议案》，同意公司 在充分保障日常经营性资金需求和投资需求、不影响公司正常生产经营并有效控制风险的 前提下，使用总额不超过 60,000 万元人民币的自有资金进行短期风险投资，投资对象主要 为证券投资；基金、理财、信托产品投资；期货投资；其他金融产品投资等。投资期限一 年，该额度可以在该期限内循环使用。 1、投资目的：最大限度地提高公司短期自有资金的使用效率，为公司和股东谋取较好 的投资回报。 2、投资额度：不超过 60,000 万元的自有资金。该额度可以在投资期限内循环使用。 3、投资对象：证券投资；基金、理财、信托产 ...

证券代码：002038 股票简称：双鹭药业 公告编号：2025-011 北京双鹭药业股份有限公司关于 2024 年日常关联交易 执行情况及 2025 年日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 2、2025 年预计关联交易事项无需提交 2024 年年度股东大会审议。 | 关 联 交 易 | 关联人 | 关联交易内容 | 关联交易 | 合 同 签 订 金 额 或 预 计 金 | 截至披露日 | 上年发生金额 | | --- | --- | --- | --- | --- | --- | --- | | 类别 | | | 定价原则 | | 已发生金额 | | | | | | | 额 | | | | 接受关联 人提供的 | 上海信忠 医药科技 | 市 场 及 产 品 调 | 自愿平 等、公平 | 1,000 万元 | 294.44 万元 | 909.10 万元 | | | | 研、市场及产品 | | | | | | | | 推广及咨询服务 | | | | | | 劳务 | 有限公司 | | 公允 | | | | | | | 费 | | ...

北京双鹭药业股份有限公司 2024 年度董事会工作报告 北京双鹭药业股份有限公司 2024 年度董事会工作报告 2024 年度，北京双鹭药业股份有限公司（以下简称"公司"）董事会全体成员严格按照 《公司法》、《深圳证券交易所股票上市规则》、《公司章程》等有关规定，本着对全体股 东负责的态度，依法履行董事会职责，积极有效地开展董事会各项工作，勤勉尽责、审慎认 真、科学决策，执行股东大会各项决议，切实维护公司和全体股东的权益，保障公司规范运 作和持续健康发展。现将董事会在 2024 年度的主要工作汇报如下： 《关于独立董事独立性自查情况的专项报告的议案》、《关于提请召开 2023 年度股东大会 的议案》。本次董事会决议公告刊登在 2024 年 4 月 24 日的《中国证券报》及指定信息披露 网站巨潮资讯网（www.cninfo.com.cn）。 2、2024 年 5 月 23 日公司召开第九届董事会第一次会议，会议审议通过了《关于选举 公司第九届董事会董事长的议案》、《关于选举公司董事会各专门委员会成员的议案》、《关 于聘任高级管理人员的议案》、《关于聘任公司内部审计部经理的议案》、《关于聘任公司 证券事务代表的 ...